VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2026

Summary

Vertex Pharmaceuticals Inc. reported strong financial performance for the first quarter of 2026, with total revenues increasing by 8% to $2,986.9 million compared to the same period in 2025. This growth was primarily driven by the continued strength of its cystic fibrosis (CF) therapies, particularly ALYFTREK and TRIKAFTA/KAFTRIO, and initial contributions from newer products like CASGEVY and JOURNAVX. Net income saw a significant surge of approximately 59.5% to $1,031.4 million, driven by robust revenue growth and a reduction in total costs and expenses, notably due to the absence of a large intangible asset impairment charge recorded in the prior year. The company also maintained a healthy cash position, with cash, cash equivalents, and marketable securities totaling $12,996.6 million, indicating strong liquidity and financial stability to support ongoing research, development, and commercialization efforts.

Key Highlights

• 1Total revenues increased by 8% to $2,986.9 million in Q1 2026 compared to Q1 2025.
• 2Net income significantly grew by 59.5% to $1,031.4 million in Q1 2026.
• 3Product revenues from CF therapies, especially ALYFTREK and TRIKAFTA/KAFTRIO, remain strong, with ALYFTREK showing substantial year-over-year growth.
• 4CASGEVY contributed $42.9 million in product revenue, a significant increase from $14.2 million in Q1 2025.
• 5Total costs and expenses decreased by 14% to $1,848.8 million, largely due to the absence of a $379 million intangible asset impairment charge recorded in Q1 2025.
• 6The company's cash, cash equivalents, and marketable securities increased to $12,996.6 million as of March 31, 2026, reflecting strong liquidity.
• 7Vertex continues to invest heavily in R&D, with expenses totaling $961.6 million, supporting a diversified pipeline.

Frequently Asked Questions